Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

2026年 11月 13日

Read More

Zai Lab Announces Participation in Investor Conferences in November 2026

2026年 11月 13日

Read More

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing

2026年 11月 13日

Read More

Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas

2026年 11月 5日

Read More

Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates

2026年 11月 5日

Read More

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

2026年 10月 23日

Read More

Zai Lab Announces $250 Million Private Placement

2026年 10月 22日

Read More

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

2026年 10月 21日

Read More